At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Founder operating in the Medical space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Yusuf Sherwani
Co-Founder & CEO of Quit Genius
Yusuf is the Co-Founder and CEO of Quit Genius. He is a Y Combinator alumni and was featured by Fast Company’s as one of their Most Creative People of 2019 as well as Forbes’ 30 Under 30 List of 2018.
Follow Yusuf Sherwani:
About Quit Genius: Quit Genius is pioneering digital therapeutics for multiple addictions.
_______
Andre Chow
Co-Founder & Co-CEO of Digital Surgery
Andre is a General Surgeon, Web coder, UX designer and all-round hacker. He has a BSc in Surgical Technology, a PhD in Tissue Engineering and leads Operations & Product. When not in the lab, Andre spends his spare time playing a variety of sports, and trying to push his french bulldog off the sofa.
Follow Andre Chow:
About Creative Destruction Lab (CDL), Digital Surgery, Medtronic, Touch Surgery: Digital Surgery is a privately-held pioneer in surgical artificial intelligence (AI), data and analytics, and digital education and training
Peter Hames
Co-Founder & CEO of Big Health
Peter Hames is CEO of Big Health, a digital medicine company he co-founded with clinical psychologist Prof Colin Espie (University of Oxford). Big Health creates automated behavioral medicine programs fuelled by tracked data, and was inspired by Peter’s difficulty in getting access to evidence-based non-drug solutions to his own insomnia. Big Health’s first product, Sleepio, is a digital sleep improvement program featuring personalized Cognitive Behavioral Therapy (CBT) techniques, delivered by virtual animated sleep expert The Prof and his narcoleptic dog Pavlov. In the world’s first placebo-controlled randomised trial for an intervention of its kind, Sleepio was shown to be comparable in effectiveness to face-to-face therapy.
Follow Peter Hames:
About Big Health, Lucky Voice, NHS England, Sleepio: Big Health is a digital therapeutics company operating a healthcare portal to offer behavioral programs for mental health issues.
Colin Espie
Co-Founder & Chief Medical Officer of Big Health
Colin Espie is Founder at Big Health.
Follow Colin Espie:
About Big Health, Sleepio, University of Glasgow, University of Oxford: Big Health is a digital therapeutics company operating a healthcare portal to offer behavioral programs for mental health issues.
Michael Anstey
Co-Founder and Chief Operating Officer of Proteorex Therapeutics Inc.
Michael Anstey is an Investment Director specialising in healthcare investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A. Michael was co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford. Michael sits on the board of Bicycle Therapeutics.
Follow Michael Anstey:
About Cambridge Innovation Capital, Proteorex Therapeutics Inc.: Expanding horizons to find cures
Peter Ward
CEO and Co-Founder of Humanity
Peter Ward is a Co-Founder and Chief Executive Officer at Humanity.
Follow Peter Ward:
About Humanity: Humanity is a healthcare company that aims to extend the healthspan of humanity.
Chris Hancock
CTO & Founder of Creo Medical
Chris has over fifteen years experience creating and developing new medical device IP focused on the use of microwave and RF energy for therapeutic applications. In 2002 he founded MicroOncology Ltd (renamed Creo Medical Ltd in 2009) to develop his ideas relating to new cancer treatment systems using state of the art semiconductor device technology to generate high frequency microwave and millimetre wave energy, and novel energy delivery and measurement techniques to identify and controllably ablate cancerous tissue. He is currently the CTO and founder of Creo Medical Ltd and holds a personal Chair in the Medical Microwave Systems Research Group at Bangor University. Chris is a Fellow of the Institute of Physics, a Chartered Physicist , Fellow of the Institute of Engineering and Technology, a Chartered Engineer and a Senior Member of the IEEE. He is a named inventor and lead author on over 100 patents/patent applications and journal publications.
Follow Chris Hancock:
About Creo Medical, Institute of Physics: Creo Medical is a developer of electrosurgical devices.
Gabriella Santosa
Co-Founder and CSO of Puraffinity
Follow Gabriella Santosa:
About Puraffinity: Puraffinity develops precision materials to target chemicals, with an initial focus on PFAS in water
Henrik Hagemann
CEO and Co-Founder of Puraffinity
Follow Henrik Hagemann:
About Puraffinity, Tech London Advocates: Puraffinity develops precision materials to target chemicals, with an initial focus on PFAS in water
Luke Heron
Co-Founder of TestCard Ltd
Luke Heron co-founded TestCard.com, a UK domiciled startup revolutionising the direct to consumer healthcare diagnostics market.
Follow Luke Heron:
About TestCard Ltd: TestCard is the medical technology company behind the eponymous at-home test kit. A partnering mobile app delivers immediate results.
Dr Andrew Botham
Co-Founder and CSO of TestCard Ltd
Follow Dr Andrew Botham:
About TestCard Ltd: TestCard is the medical technology company behind the eponymous at-home test kit. A partnering mobile app delivers immediate results.
Houman Ashrafian
Managing Partner & Founder of SV Health Investors
Houman Ashrafian is the Managing Partner at SV Health Investors.
Follow Houman Ashrafian:
About Catamaran Bio, Cellinta, Enara Bio, Karus Therapeutics, Sitryx Therapeutics, SV Health Investors, Zarodex Therapeutics: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Gregg Sando
Founder & former Chief Executive Officer of Kuur Therapeutics
Gregg Sando is the founder and CEO of Cell Medica. After a career in investment banking based both in London and New York, he completed his Immunology MSc degree at the medical school of Imperial College. Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in cooperation with a small group of the leading clinicians and immunologists who were pioneering this new mode of medical treatment. (B.A. Biochemistry, Harvard University; M.B.A. University of Chicago; MSc Immunology, Imperial College London).
Follow Gregg Sando:
About Kuur Therapeutics: Kuur Therapeutics is committed to transforming the lives of patients with cancer & is leading the development cell therapies.
Rafael López Schietekat
Founder & Managing Director of Diagnostikare
Follow Rafael López Schietekat:
About Diagnostikare: The first data-driven patient-centric virtual primary care platform in Mexico.
Stewart Whiting
Tech Co-Founder & CTO of Current Health
Follow Stewart Whiting:
About Current Health: We help healthcare reduce risk & cost by monitoring, managing and engaging patients at home.
Emil Hewage
Co-Founder & CEO of BIOS
Emil’s academic background is as a PhD researcher in computational neuroscience and machine learning. He brings knowledge of neural signalling and signal processing with over 7 year’s industrial & academic R&D experience. He has previously developed medical devices with Siemens Healthcare and Sphere Medical as well as having held roles in finance and medical and cleantech startups.
Follow Emil Hewage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Oliver Armitage
Co-Founder & CSO of BIOS
Oliver Armitage is Co-Founder and Chief Scientific Officer at BIOS, a leading neural engineering startup. Oliver has always had a vision that the human body could be repaired or made better through augmentative technology and how that can be used to improve people’s lives. He studied for his PhD at the University of Cambridge in Bioengineering, working in the world-renowned Nanoscience Centre. He specializes in tissue interfaces and engineering to allow technology to be fused with the body. Oliver was recently named to Forbes 30 Under 30 2018.
Follow Oliver Armitage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Sandeep Bansal
Founder & CEO of Medic Creations
Dr Bansal graduated from Imperial College London with a MSc in Paediatrics and Child Health. In 2013 he started his General Practitioner training at Oxford Deanery where he was also Trainee Lead, representing Oxford Deanery for the Associates in Training (AiT) committee in their quarterly meetings at Royal College of General Practitioners. From his professional experience and feedback from his peers, DrBansal raised the concerns of poor Information Governance (IG) compliance around sharing patient dataat AiT meetings. With the AiT board’s response of their inability to offer an alternative solution, Dr Bansalcarried out a survey to understand the extent of the problem in 2014. The survey for his 180 colleagues went viral and he received 2050 responses confirming the poor IG compliance practice, predominantly around the use of WhatsApp. In 2014 he set up Medic Creations and created the innovative app MedicBleep to enable secure and reliable clinical communication for primary, secondary and community care. With enabling communication across healthcare organisations and professionals, Medic Bleep empowerstrue interoperability, the future of healthcare management and innovation. Medic Creations was selected for Web Summit Alpha 2015 and is listed in the Journal of mHealth’s top100 Global Digital Companies for 2016 and 2017.
Follow Sandeep Bansal:
About Bennett Coleman and Co Ltd, Harvard Medical School, Medic Creations, shl.vc: Revolutionising Communications in Healthcare
Andrew Shepherd
Co-Founder & Managing Director of Omega Diagnostics
Andrew Shepherd is the Founder and Managing Director of Omega Diagnostics Limited. He is responsible for corporate strategy, general management, sales and marketing and technical direction. He has been involved in the medical diagnostics industry for the last 35 years. He started his career in 1974 by holding technical positions at G.D. Searle Limited and then attended university, graduating with a Bachelor of Science in Biology. He then moved into a sales and marketing position at Cambridge Life Sciences plc in 1981, before establishing his first diagnostics company, Cambridge Biomedical Limited in 1982. In 1986 he moved to Scotland to join Bioscot Limited and shortly afterwards, established Omega. Shepherd used his technical experience and knowledge of exporting to oversee the growth of the export of Omega products to exceed £2 million per annum. Omega now exports to over 100 countries around the world, and he travels regularly to many of the countries in which Omega customers are based. Shepherd is an active member of a number of relevant trade associations and was a member of the Scottish Exports Forum, a body which reported to the Scottish Parliament to oversee and guide the export activity of Scottish Development International. Mr Shepherd was also a member of the Bill & Melinda Gates Foundation’s (BMGF) Global Health Diagnostics Forum, which provides direct guidance to BMGF in advising on future investments in worldwide diagnostics programmes for developing countries.
Follow Andrew Shepherd:
About Global DX Ltd, Omega Diagnostics: Omega Diagnostics provides IVD products for use in hospitals, blood banks, clinics, and laboratories.
Nader Alaghband
Co-Founder & CEO of Ampersand Health
Follow Nader Alaghband:
About Ampersand Health: Ampersand creates innovative digital medicines for complex long term conditions, using behavioural and data-science.
Amit Nathwani
Founder & Chief Scientific Officer of Freeline
Amit is renowned for his pioneering work on gene therapy for haemophilia B, and was first to show successful correction of bleeding diathesis in patients with severe haemophilia B. Amit is the Director of the Katharine Dormandy Haemophilia Centre at the Royal Free Hospital, and a Senior NIHR Investigator. He is also Professor of Haematology at UCL. He graduated in Medicine from the University of Aberdeen in 1984. In 1997 he moved to St. Jude Children’s Research Hospital, Memphis, USA, to work with Dr Arthur Nienhuis on adeno-associated virus mediated gene transfer. Here he started his pioneering work on gene therapy for haemophilia B. In 2001 he returned to University College London as a Senior Lecturer in Haematology and a Consultant to the National Blood Services in the UK. He was the first to show successful correction of bleeding diathesis in patients with severe haemophilia B, using a distinct gene transfer approach developed in collaboration with Dr’s Davidoff and Nienhuis at St Jude Children’s Research Hospital.
Follow Amit Nathwani:
About Freeline: Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.
Mohammed Tayeb
Co-Founder and Chief Operations Officer of Medicalchain
Internet entrepreneur and founder of several technology and e-commerce start-ups. Mohammed specialises in bringing together technological efficiencies to the business world. Most recent start-up is ReadyCache, a web acceleration platform using Multi-CDN technology. Mohammed holds an Executive MBA from University of Oxford and a BSc in eCommerce from Brunel University, London.
Follow Mohammed Tayeb:
About Dynistics, Medicalchain: Medicalchain is a decentralized platform that enables secure, fast and transparent exchange and usage of medical data.
Abdullah Albeyatti
CEO & Co-Founder of Medicalchain
Dr Albeyatti graduated from Imperial College London as a doctor in 2011. He has always had a passion for innovation and problem solving and has developed solutions to inefficiencies he found whilst working in the UK National Health Service. In 2016 he co-founded Medicalchain, initially as Discharge Summary – an application used in hospitals to generate accurate medical reports on patients, before they are discharged. Dr Albeyatti’s career in medicine started with surgical training in London and has moved on to general practice with a view to continuing his ENT passion and furthering his management aspirations. He continues to work in Accident and Emergency to sharpen his clinical skill set.
Follow Abdullah Albeyatti:
About dischargesummary.co.uk, Medicalchain, MyClinic, NHS, NHS England: Medicalchain is a decentralized platform that enables secure, fast and transparent exchange and usage of medical data.
Hannah Sore
Founder and CEO of PharmEnable
Follow Hannah Sore:
About PharmEnable: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
John E. Milad
CEO & Founder of Quanta
John E. Milad is a global healthcare executive, board member, investor, speaker and author. He has a career spanning over 25 years, with experience working in various senior positions in the healthcare sector, including NBGI Ventures, Atlas Venture, Nitec Pharma and Nomura. Currently, John is Chief Executive Officer and founding board member at Quanta Dialysis Technologies, where he recently raised $245m in Series D funding. An executive with international experience in building and growing successful healthcare companies, John had the vision and belief that core technology of managing fluidics on a disposable cartridge could be developed into a portable hemodialysis device with the potential to address multiple unmet needs in the $93 billion global dialysis market. John is a regular speaker and panelist at global medtech and investment conferences and has co-authored 4 peer-reviewed papers.
Follow John E. Milad:
About NBGI Ventures, Quanta: Quanta develops an advanced haemodialysis systems for use in the home and clinic.
Ali Rezaei Haddad
CEO and Founder of NeuroNav
Ali is a neurosurgical resident in London and an NHS Clinical Entrepreneur. Prior to this, he completed his Academic Foundation Training in the Medical Sciences Division at the University of Oxford undertaking research in the field of neuroimaging. He graduated with first class honours in Neurosciences BSc at Imperial College London, and he holds honorary research positions at the University of Oxford and St George’s Medical School. Ali co-founded the internationally acclaimed GoodSAM app used by the NHS, in which clinically trained individuals sign up as volunteers to respond to life-threatening emergency calls. He also directed and curated the Imagining the Future of Medicine at the Royal Albert Hall in partnership with TEDMED, attended by a live audience of 5,000 people. Inspired by the lack of user friendly and affordable neuronavigation solutions worldwide, he founded NeuroNav to democratise access to neurosurgery navigation solutions.
Follow Ali Rezaei Haddad:
About Imperial College Healthcare NHS Trust, NeuroNav: An augmented reality neuronavigation platform powered by computer vision and machine learning.
Seyed-Mahdi Khaligh-Razavi
Co-Founder and Chief Science Officer of Cognetivity Neurosciences
Seyed-Mahdi Khaligh-Razavi is the Co-Founder and Chief Science Officer at Cognetivity Neurosciences.
Follow Seyed-Mahdi Khaligh-Razavi:
About Cognetivity Neurosciences: Cognetivity Neurosciences is a Platform technology for early, rapid and easy detection of dementia.
Carina Cunha
Co-Founder & CEO of Be Nosy
Carina is a business strategist and inventor of Nosy with passion for science, sales and marketing. In her former role as MD and Launcher of Crimson Education Europe, she created sales, marketing and service delivery teams from scratch, achieving millions in ARR and 150%+ YoY growth. Prior to working with startups Carina was corporate strategist at JPMorgan, Strategy Consultant at Accenture, Investment Banker at Credit Suisse, and a fashion model with Elite. Carina is also an innovation and commercial consultant through Meta Strategy and Founders Intelligence where she helps startups and scale-ups find product-market fit and corporates build new revenue lines. She has a B.A. from Columbia University and PgD. from the University of Edinburgh.
Follow Carina Cunha:
About Be Nosy: Nosy is a MedTech startup developing wearable air filter and air pollution tracking network.
David Tuch
Founder & Executive Chairman of Lightpoint Medical
David Tuch is the Founder and CEO of Lightpoint Medical. He has more than a decade of experience in the medical imaging and pharmaceutical sectors. Previously, he was Head of Research Alliances at GE Healthcare and Head of Clinical Imaging at Novartis. Before joining industry, Dr. Tuch served on the faculty of Harvard Medical School and Massachusetts General Hospital, Department of Radiology. He is currently an Honorary Senior Lecturer in the Imperial College, Department of Bioengineering. Dr. Tuch holds a PhD from MIT and Harvard Medical School, a BA from the University of Chicago, and has completed executive education at INSEAD.
Follow David Tuch:
About Lightpoint Medical, Lucida Medical: Lightpoint Medical, a medical device company, develops intra-operative imaging technology that can detect cancer during surgery.
Sophie Dundovic
Co-Founder of Parasym
Sophie Dundovic is a Co-founder at Parasym.
Follow Sophie Dundovic:
About Parasym: Parasym is a neurotechnology company focused on providing innovative neurostimulation products that improve quality of life.
Mosin Badkar
Co-Founder and VP of Cardiac Design Labs
Mosin Badkar is responsible for product R and D and Algorithms. His scope includes design of new products, prototyping of design and proof of concept. His scope also includes planning and tracking of new product designs, system level and various software development activities.
Follow Mosin Badkar:
About Cardiac Design Labs: Cardiac Design Labs is into designing, developing, deploying and selling intelligent devices for medical purpose.
James Noble
Founder & CEO of Adaptimmune
James Noble has served as our full-time Chief Executive Officer since March 2014 and part-time CEO from July 2008 to March 2014 and is one of our co-founders. From July 2008 until March 2014, Mr. Noble was also part-time CEO of Immunocore. Mr. Noble has 24 years of experience in the biotech industry. He has held numerous non-executive director positions, including at CuraGen Corporation, PowderJect Pharmaceuticals plc, Oxford GlycoSciences plc, MediGene AG, and Advanced Medical Solutions plc. Mr. Noble is also Deputy Chairman of GW Pharmaceuticals plc and a non-executive director of Immunocore Limited. Mr. Noble is qualified as a chartered accountant with Pricewaterhouse Coopers and spent seven years at the investment bank Kleinwort Benson Limited, where he became a director in 1990. He then joined British Biotech plc as Chief Financial Officer from 1990 to 1997. Mr. Noble was previously Chief Executive Officer of Avidex Limited, a privately held biotechnology company that was our predecessor, from 2000 to 2006. Mr. Noble holds an MA from the University of Oxford.
Follow James Noble:
About Adaptimmune, Advanced Medical Solutions, Curagen Corporation, MediGene, Oxford GlycoSciences, PowderJect Pharmaceuticals: Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Ian Mills
Director of Software Engineering and Co-Founder of Clinpal
Ian has been directly involved in the development of some of the leading, and most advanced EDC systems brought to market in the last 15 years. At eClinicalHealth, he continues to lead from the front by supporting clients integrate and extend their eClinical solutions. Ian is an expert in agile software development methods, and besides his hands-on technical prowess he has take the lead in ensuring organizations he works with have bullet proof auditability throughout their product development lifecycle. All work carried out at eClinicalHealth follows either our own rigorous agile Software Development LifeCycle, or, if preferred our sponsors. Ian’s EDC products have been used globally by companies such as Roche, Novartis, Merck and Johnson & Johnson. Ian is a master of CDISC standards – ODM specifically – as well as Web technologies for regulated industries that include; RUP, XP, UML, SCRUM, Agile Development, JEE (JPA, JSF, JSP, JMS, JMX, JTA), Spring Framework, Eclipse, Hibernate, Tapestry, Web Services, JavaScript, Ajax, GWT, JQuery, SQL (Oracle, DB2, MySQL), XML, NoSQL Databases (ObjectStore, Mongo, CouchDB), C/C++, Groovy, Python. Besides Ian’s computing language proficiency, Ian is also fluent in both English and German.
Follow Ian Mills:
About Clinpal: Clinpal is a leading cloud-based digital patient recruitment and engagement platform.
Yiannis Kiachopoulos
CEO, Co-Founder of Causaly
Follow Yiannis Kiachopoulos:
About Causaly: Causaly is teaching computers to read all knowledge in Biomedicine
Artur Saudabayev
Co-Founder, CTO of Causaly
Follow Artur Saudabayev:
About Causaly: Causaly is teaching computers to read all knowledge in Biomedicine
Tess Cosad
Co-Founder & CEO of Bea Fertility
Tess Isabelle Cosad is the Chief Executive Officer and Co-Founder of Bea Fertility.
Follow Tess Cosad:
About Bea Fertility: Bea Fertility is a monthly subscription program that provides users with at-home fertility treatment and ovulation tracking.
David O’Rourke
Co-Founder and Chief Scientific Officer (CSO) & Chief Innovation Officer (CIO) of Bea Fertility
David O’Rourke is the Chief Operating Officer and Co-Founder of Bea Fertility.
Follow David O’Rourke:
About Bea Fertility, Vitrolife: Bea Fertility is a monthly subscription program that provides users with at-home fertility treatment and ovulation tracking.
Zubair Ahmed
CEO & Founder of MedicSpot
Follow Zubair Ahmed:
About MedicSpot: MedicSpot gives patients convenient and quick access to healthcare using the latest advancements in telemedicine
Richard Vincent
CEO & Co-Founder of FundamentalVR
Richard has 20+ years’ experience of building international businesses and has throughout his career sought opportunities for positive market disruption through technological application. It was this desire that led him to co-found FundamentalVR to help address an age-old problem for the medical market; how to create safe, realistic, measurable spaces to learn and develop skills. In his role as CEO Richard is responsible for building a world class team of medical, learning and technologist who together can realise the company’s ambition of creating the world’s first global, haptically enabled, low cost ‘flight simulator for surgeons’.
Follow Richard Vincent:
About Fundamental Surgery, FundamentalVR: FundamentalVR delivers VR haptic ‘flight simulators’ for surgery creating a safe, measurable & repeatable space to refine to refine skills.
Chris Scattergood
CRO & Founder of FundamentalVR
A key part of his role at Fundamental, Chris visits leading surgeons, educators, hospital groups, bodies and device manufacturers across the US to understand their educational needs and requirements for successful integration into our learning platform, and continue to develop our product to support those needs. As one of the co-founders of Fundamental, in 2014 Chris and his co founder saw the opportunity to invest in Virtual Reality as the next tech platform after mobile to revolutionise the way we communicate, share and learn together. From his experience in the Healthcare sector, it was clear that VR presented a clear opportunity to make a real difference in way education could be delivered for Health care professionals.
Follow Chris Scattergood:
About Fundamental Surgery, FundamentalVR: FundamentalVR delivers VR haptic ‘flight simulators’ for surgery creating a safe, measurable & repeatable space to refine to refine skills.
Brian Falzon
Founder of Veryan Medical
Brian G. Falzon is the Head of the School of Mechanical and Aerospace Engineering, and Professor of Composite Materials and Aerostructures at Queen’s University Belfast. Between 2013 and 2017, he held the prestigious Royal Academy of Engineering – Bombardier Chair in Aerospace Composites. Between 2008 and 2012 he was the Foundation Chair in Aerospace Engineering at Monash University in Melbourne, Australia, where he was also Director of Research and Head of the Aerospace Engineering programmes. Between 1996 and 2008, Professor Falzon was at Imperial College London where he joined as a postdoctoral research fellow before becoming an academic staff member. Professor Falzon graduated with a PhD in Aeronautical Engineering from the University of Sydney in 1996 and was awarded the Golden Jubilee graduate prize for his research into postbuckling composite aerostructures. He also gained a Master of Engineering in Aeronautical Engineering with first class honours and a Bachelor of Science with a double major in Physics and Pure Mathematics from the same University. He is a Fellow of the Royal Aeronautical Society Professor Falzon is internationally renowned for his work on the analysis, design, manufacture and testing of advanced composite aerostructures and has published over 120 peer reviewed journal and conference papers in this area. He has fostered extensive industry and academic collaborations with partners from Europe, Australia, India and China. In 2008 Professor Falzon was awarded the George Taylor Prize by the Royal Aeronautical Society for the best paper published in 2007 in the design, construction, production and fabrication of aircraft structures. In 2009 he was honoured with an Australian Leadership Award, from the Australian Davos Connection, in recognition of his contribution to issues of national importance and demonstrated leadership in his field. In 2016 he was the recipient of Queen’s University Belfast’s Postgraduate Supervisory Excellence Award. He is a Chartered Engineer and a member of a number of professional organisations and scientific committees. Between 2006 and 2009 he was a member of the UK’s EPSRC Peer Review College and in 2010 and 2012 he was selected to serve on the Research Evaluation Committee panel for the Australian Research Council’s Excellence in Research for Australia exercise which is equivalent to the UK’s Research Excellence Framework (REF). Professor Falzon is also co-founder of Veryan Medical Limited, a company spin-off from Imperial College London.
Follow Brian Falzon:
About Queen’s University Belfast, Veryan Medical: Veryan Holdings is a medical device company developing three dimensional vascular stents for peripheral vascular disease.
Michalis Papadakis
CEO & Co-Founder of Brainomix
Dr Michalis Papadakis is the CEO and co-founder of Brainomix. He leads the management team, commercial strategy, fund raising, and corporate partnerships. He has grown the company from the ground up, building the company’s global presence and has raised over £15 million of private investment and public funding. When he founded Brainomix he was the Scientific Director of the preclinical stroke lab at the University of Oxford. He has a BSc Honours in Biochemistry from Imperial College London and a PhD in neurosciences from UCL School of Pharmacy. He has been an invited speaker at international scientific and innovation conferences
Follow Michalis Papadakis:
About Brainomix: Brainomix specializes in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions
Vibhor Gupta
Director and Founder of Pangaea Data
Vibhor is an entrepreneur in residence at Nexgen Capital Ventures where he is involved in deal flow and leading creative technological opportunties within Life Sciences following his breadth of experience in industry and academia over the last 16 years. Prior to this role, Vibhor has served in various positions ranging from technical bioinformatics roles, sales (of software technology products) and executive management. Vibhor started and built the European business for Quantum Secure, which was an enterprise software solutions provider and was successfully acquired in 2015. Most recently he served as a Senior Vice President at Seven Bridges Genomics which provides cloud (SaaS) based bioinformatics solutions for the Life Sciences industry. Vibhor has also worked as a management and technology consultant for Deloitte. His academic career focused on bioinformatics, epigenetics and molecular biology studies in oncology and infectious diseases. Vibhor has access to an extensive network in the industry and was recently honoured as an advisor to two prominent organisations, HealthEx and FrontLine Genomics. He was also a Technology Lead on ASIS’s UK committee, which is the largest professional body for CSOs and CISOs in the world.
Follow Vibhor Gupta:
About Pangaea Data: Pangaea Data provides a machine learning-based software solution making scientific and clinical data more meaningful.
Global CEO & Co-Founder of Andiamo
Follow Naveed Parvez:
About Andiamo, UnLtd: Custom medical wearables platform
Nick Morrell
CEO and co-Founder of Morphogen-IX
Nick is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge, based in the Department of Medicine. He has 25 years of experience working in the field of pulmonary arterial hypertension (PAH), and is the Research Director of the National Pulmonary Hypertension Service at Papworth Hospital. His research spans clinical translational studies, experimental medicine, genetics, cell and molecular biology and preclinical models of disease. He has published over 200 papers in this field and is an internationally recognised authority on the pathobiology of PAH.
Follow Nick Morrell:
About Morphogen-IX, Papworth Hospital, University of Cambridge: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Wei Li
Co-Founder of Morphogen-IX
Wei Li, Co-Founder at MORPHOGEN-IX LIMITED.
Follow Wei Li:
About Morphogen-IX: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Mathieu de Beaumont
Co-Founder / Director of Dementech
Co-Founder of Dementech Neurosciences
Follow Mathieu de Beaumont:
About : Neurology & Psychology experts
Michel Rabhi
Founder and Director of Dementech
Owner and Director at Dementech Neurosciences
Follow Michel Rabhi:
About : Neurology & Psychology experts
Pablo Graiver
President and Founder of Antidote.me
Pablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.
Follow Pablo Graiver:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Raj Vora
Founder & Managing Director of Revital
Follow Raj Vora:
About Revital: Revital is an independent company with a mission to care for the wellbeing and health of our customers.
Alex Hamilton
Founder of DocTap
Alex had the idea for DocTap whilst struggling to get an NHS GP appointment for his chronic back pain arising from his time in the Armed Forces. When he was unable to find a convenient, affordable GP surgery he knew he had to build one. 18 months later, DocTap was born. He is delighted to have attracted such a talented team to help build DocTap. And here they are.
Follow Alex Hamilton:
About DocTap: DocTap provide convenient, expert GP care from their network of central London clinics.
Daniel Faber
Founder of DocTap
Follow Daniel Faber:
About DocTap: DocTap provide convenient, expert GP care from their network of central London clinics.
Eoin McKinney
Chief Scientific Officer & Co-Founder of PredictImmune
Eoin is a Wellcome-Beit intermediate Research Fellow in the Department of Medicine at the University of Cambridge and an honorary consultant in nephrology and transplantation in Cambridge University NHS hospitals Foundation Trust. He obtained a first-class degree in pre-clinical medicine from Keble College, Oxford University in 1999 and graduated in clinical medicine with honours from Edinburgh University in 2002. His primary interest is the use of systems immunology approaches to translate high throughput analyses of autoimmune disease datasets into clinical practice.
Follow Eoin McKinney:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Kenneth Smith
Co-Founder & Chief Medical Officer of PredictImmune
Professor Ken Smith is Professor of Medicine and Head of the Department of Medicine at the University of Cambridge. He trained in nephrology (FRACP, FRCP) and clinical immunology (FRCPA) and completed a PhD at the WEHI in Melbourne. His laboratory runs a translational programme in autoimmune disease (particularly inflammatory bowel disease, vasculitis and SLE) that has led to the discovery of a novel prognosis-predicting biomarker currently in clinical trials and the identification of genes and pathways involved in disease pathogenesis.
Follow Kenneth Smith:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Paul Lyons
Vice President of Platform Delivery & Co-Founder of PredictImmune
Paul is a Principal Research Associate in the Department of Medicine at the University of Cambridge. He has over 25 years of experience in molecular and cellular biology including Senior Scientist positions in the Dept. Medical Genetics, University of Cambridge, Dept. Surgery, University of Oxford and the Rosalind Franklin Centre for Genomics Research. His primary research interest is the application of high throughput genomic approaches to better understand the genetic and molecular basis of autoimmune disease.
Follow Paul Lyons:
About PredictImmune: Providing tools to physicians in the treatment of patients with immune-mediated disease, through prediction of long term clinical prognosis.
Ali Moiyed
CEO & Founder of Aerobit Health
Follow Ali Moiyed:
About Aerobit Health: Breathing New Life Into Asthma Care
Krishan Ramdoo
CEO and Founder of Tympa Health Technologies LTD
Krishan Ramdoo is the CEO and Founder of TympaHealth Technologies.
Follow Krishan Ramdoo:
About Tympa Health Technologies LTD: TympaHealth are a team of doctors and technology experts united in their vision of helping the world to hear.
Yeshwanth Pulijala
Founder & CEO of Scalpel
Follow Yeshwanth Pulijala:
About Scalpel: Scalpel provides a platform to optimize surgical procedures in clinics and hospitals.
Alex Hooi
Chief Medical Officer / Founder of Callaly
Inventor of the Tampliner®, and a co-founder at Callaly.He is also an NHS Gynaecologist, Consultant Specialist and Clinical Director of the Barking Havering and Redbridge University Hospitals NHS Trust and Fellow of the Royal College of Obstetricians and Gynaecologists.
Follow Alex Hooi:
About Callaly: Callaly is a period care company that develops and manufactures innovative feminine care products.
Thang Vo-Ta
CEO & Co-Founder of Callaly
Co-founder & CEO at Callaly.Thang is a graduate of MIT and started his career in Goldman Sachs in NYC & London.
Follow Thang Vo-Ta:
About Callaly: Callaly is a period care company that develops and manufactures innovative feminine care products.
Andrew McElroy
Co-Founder & Strategic Project Manager of Exvastat
Andrew McElroy is the CEO, Director & Founder of EligoChem & he attended University of Cambridge in 1977.
Follow Andrew McElroy:
About EligoChem, Exvastat, The Research Network: Exvastat is an innovative, preclinical-stage pharmaceutical company.
Paweł Sieczkiewicz
Co Founder & CEO of Telemedi
Graduate of Warsaw University of Technology, experienced project manager (web/mobile apps), php programmer. Founder of an SSF software house. 2x champion of Poland in kickboxing.
Follow Paweł Sieczkiewicz:
About Telemedi: Trusted partner in digital healthcare
Napala Pratini
Co-Founder of Habitual
Napala Pratini is the Founder at Habitual.
Follow Napala Pratini:
About Habitual: Digital therapeutics & nutritional treatment for type 2 diabetes reversal.
Ian Braithwaite
CEO & Co-Founder of Habitual
Ian Braithwaite is the CEO and Co-Founder at Habitual.
Follow Ian Braithwaite:
About Habitual: Digital therapeutics & nutritional treatment for type 2 diabetes reversal.
Manuel Corpas
Chief Scientist and Founder of Cambridge Precision Medicine
Manuel Corpas is the chief scientist and co-founder at Cambridge Precision Medicine. He is a human genome scientist developing comprehensive genetic tests and training courses to help clinicians optimise their patient’s health and prevent disease.
Follow Manuel Corpas:
About Cambridge Precision Medicine: Cambridge Precision Medicine Ltd. is a company dedicated to research, education and consulting.
Agnieszka Chomka
Co-Founder and Head of R&D of BioMe Oxford
Agnieszka is an intestinal immunologist at the Kennedy Institute for Rheumatology, University of Oxford. Her main research interests focus on the microbial-host interactions in the large intestine. She was awarded the prestigious Wellcome Trust scholarship at the University of Oxford to conduct her research into the role of a tissue-resident regulatory immune cell population in the gut. Agnieszka has published her results in top peer-review research journals.
Follow Agnieszka Chomka:
About BioMe Oxford, Globe Life Sciences: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Soren Krogsgaard Thomsen
Co-Founder, CEO and Managing Director of BioMe Oxford
Soren is a medical scientist at the University of Oxford, with a background in the natural sciences and genetics research. He previously worked as a consultant for pharma and OBR consulting, and has published on his experiences as an academic entrepreneur. Soren’s current research is focused on translating large-scale genetic data into mechanisms for disease to inform new therapeutic strategies. He dreams of one day enabling similar population-wide microbiome studies using the platform technology under development at BioMe Oxford Ltd.
Follow Soren Krogsgaard Thomsen:
About BioMe Oxford, Vertex Pharmaceuticals: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Patrick Albers
Co-Founder and Head of Technology of BioMe Oxford
Follow Patrick Albers:
About BioMe Oxford, Wellcome Trust Sanger Institute: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Samantha Payne
Co Founder & COO of Open Bionics
Samantha Payne is the co founder of Open Bionics; a robotics company developing assistive devices that enhance the human body. The company has won multiple awards for Engineering and Innovation including two British Engineering Excellence Awards and the James Dyson award for innovative design. Open Bionics works with companies like Disney to children with limb differences into bionic superheroes. They were the first company to bring affordable multi-grip bionic hands to the National Health Service in the UK.
Follow Samantha Payne:
About Open Bionics: Open Bionics is a robotics company creating affordable 3D-printed bionic hands for amputees, researchers and makers.
Guido Franzoso
Scientific Founder of Kesios Therapeutics
Franzoso joined Imperial College London in June 2007 and is Head of the Centre for Cell Signalling and Inflammation and Professor and Chair of Signal transduction and Inflammation. He was previously at the University of Chicago for 10 years. Franzoso, is the principal founder of Kesios Therapeutics, a spin-out from Imperial College London founded in 2012. Franzoso’s work is highly regarded by the scientific community, as evidenced by numerous high-impact publications in journals, such as, Nature, Science, Cell, Immunity, Nature Cell Biology and Cancer Cell and he has been awarded substantial funding to pursue his research. Recognising the need to translate this research into healthcare benefit, Franzoso was able to raise £3.7M from the MRC for a multi-centre Phase I/IIa trial of DTP3 in multiple myeloma and he has also successfully achieved substantial project funding for both basic and clinical research from the MRC, CRUK and NIH (US). Franzoso owns several patents on intellectual property related to his research. Franzoso holds a medical degree from the University of Padua medical school, Italy and a Ph.D. in microbiological sciences from the Institute of Microbiology at the University of Padua.
Follow Guido Franzoso:
About Imperial College London, Kesios Therapeutics: Kesios Therapeutics, a London, UK-based oncology drug discovery company
Eric Miska
Co-Founder of Storm Therapeutics
Eric is the Herchel Smith Professor of Molecular Genetics and a Senior Group Leader at the Gurdon Institute at the University of Cambridge. He has an appointment as associated faculty at the Cambridge Systems Biology Centre and the Cancer Research UK Cambridge Research Institute. Eric was an EMBO Young Investigator and is a full member of EMBO since 2012. Eric is the 2013 recipient of the Hooke Medal awarded by the British Society of Cell Biology. He joined the faculty of the Wellcome Trust Sanger Institute in Hinxton in 2014 and is a Senior Investigator of the Wellcome Trust. Eric studied mathematics, physics and biology at Heidelberg, Berlin and Mainz and holds a BA in Biochemistry from Trinity College, Dublin. He received his PhD in Pathology from the University of Cambridge, UK, in 2000, working with Professor Tony Kouzarides, and was a postdoctoral fellow in the laboratory of Nobel laureate Bob Horvitz at the Massachusetts Institute of Technology, Cambridge, MA, USA from 2000 to 2004. He started his own research group at the Gurdon Institute in 2005.
Follow Eric Miska:
About Storm Therapeutics, University of Cambridge: Targeting pathways that modify RNA to deliver novel cancer therapeutics
Ashley Rudland
Co-Founder of Circular Wave
Ashley Rudland is the co-founder of Circular Wave. He was the founder and principal consultant at DeepSilver Solutions. He is also a former co-founder and CTO at World City Limited.
Follow Ashley Rudland:
About Circular Wave: Temporary Staffing Platform for the NHS
Edward Ungar
Co-Founder & CEO of Pharmacierge
Edward Ungar is a Co-founder at Pharmacierge.
Follow Edward Ungar:
About Pharmacierge: The free e-prescribing service chosen by Private GPs and Consultants to deliver medication to their patients nationwide
Robert Ungar
Co-Founder of Pharmacierge
Robert Ungar is a Co-Founder at Pharmacierge.
Follow Robert Ungar:
About Pharmacierge: The free e-prescribing service chosen by Private GPs and Consultants to deliver medication to their patients nationwide
Shankar Balasubramian
Co-Founder and Director of Cambridge Epigenetix
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN. Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine. Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Royal Medal (2018), the RoyalSociety Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the Academy of Medical Sciences and a member of EMBO.
Follow Shankar Balasubramian:
About Ahren Innovation Capital, Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
David Sibbald
CEO and Co-Founder of Aridhia Informatics
David Sibbald is the co-founder and CEO of Aridhia, a health data science company which develops and runs a cloud-enabled Digital Research Environment for clinical research, precision medicine and healthcare applications. David is the Founder and Trustee of the Kate MacAskill Foundation, a charitable organisation providing education, care and micro-enterprise funding for children and young adults in the developing world and is Chairman of the Johari Foundation. He has been awarded honorary doctorates from Glasgow University, Glasgow Caledonian University, the University of Paisley and the University of Strathclyde for services to Scottish science and philanthropy. He is a Fellow of the Royal Society of Edinburgh, Scotland’s National Academy of Science and Letters. In the 2010 New Year Honours List, David was awarded an OBE for charitable services in Scotland and overseas.
Follow David Sibbald:
About Aridhia Informatics, Kate MacAskill Foundation: Aridhia informatics provides biomedical informatics and analytics services to improve the management of chronic diseases.
Ioannis Papakonstantinou
Founder of Echopoint Medical
Ioannis holds a PhD in Optical Interconnections from University College London. After his PhD, he joined Sharp Laboratories of Europe to work on the design and fabrication of photonic nanostructures for Optical Displays. Subsequently, he joined CERN-European Organisation of Nuclear Research where he led the work on fibre optic communication systems for particle physics detectors. He is currently a Professor of Photonics and Nanofabrication in the Department of Electronic and Electrical Engineering at UCL where he leads the Photonic Innovations Lab (www.ee.ucl.ac.uk/pilab). The mission of his lab is to exploit the synergies between nanotechnology and photonics for energy and biomedical applications. Ioannis has authored/co-authored over 130 journal publications and conference proceedings and is the holder of over 10 patent families.
Follow Ioannis Papakonstantinou:
About Echopoint Medical: Echopoint Medical is a medtech company
Richard Colchester
Founder of Echopoint Medical
Richard was born in Ipswich, U.K., in 1990. He received the MSci degree in physics from Imperial College London, London, U.K., in 2012, and the MRes degree in photonic systems development from University College London, London, U.K., in 2013. He finished his Ph.D. in Medical Physics and Biomedical Engineering at University College London in 2016. On completion of his Ph.D. he was award an EPSRC Doctoral Prize Fellow at University College London to develop an all-optical ultrasound imaging system for cardiovascular procedures. Since, he has received a Royal Academy of Engineering research fellowship to continue his work in this field and establish his research. His research interests include developing interventional medical imaging systems based on laser-generated ultrasound and photoacoustics.
Follow Richard Colchester:
About Echopoint Medical: Echopoint Medical is a medtech company
Katerina Spranger
Founder and CEO of Oxford Heartbeat
Katerina is the Fellow of the Royal Academy of Engineering. She holds a PhD in Biomedical Engineering from the University of Oxford and was previously a researcher in AI at the Sony Computer Science Laboratory in Paris.
Follow Katerina Spranger:
About Oxford Heartbeat, Royal Academy of Engineering: Oxford Heartbeat makes cardiovascular surgery more accurate and safe.
Edward Green
Founder & Chief Executive of CHAIN Biotechnology
Edward is a serial biotech entrepreneur, having founded Green Biologics and built it into a world leader for butanol fermentation. He is a microbiologist with over 25 years’ experience with anaerobic bacteria, obtaining a PhD in Biochemical Engineering from the University of Manchester Institute of Science and Technology. He has pioneered technical improvements in microbial strain improvement and fermentation process development for industrial biotechnology applications contributing to numerous scientific publications and patents. He recently founded CHAIN Biotech, a microbiome Company focused on development and commercialisation of microbial technology for the production and delivery of biotherapeutics. Edward participates in the IB Leadership Forum, several NIBB management boards; C1NET and LBNET and BBSRC advisory panels for Bioenergy and Industrial Biotechnology.
Follow Edward Green:
About CHAIN Biotechnology, Green Biologics: CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases.
Basil Omar
Founder & Chief Commercial Officer of CHAIN Biotechnology
Basil has a PhD in Physics from Loughborough University and MBA from Warwick Business School. He has held senior technical management roles in semiconductors, electronic displays and advanced materials with Philips Electronics and Sharp Corporation. Basil also has a background in Management Consultancy with PRTM (now PwC) and Grant Thornton, and has held senior business development and marketing roles at Transco/National Grid and Green Biologics. Basil via Woodbridge Innovation has supported numerous early stage companies in a range of high tech fields including clean energy and industrial biotech. Basil launched and ran the University of Gloucestershire’s business incubation hubs and is co-founder of the Gloucestershire Angel Investment Network. Basil is a farming and classic car enthusiast.
Follow Basil Omar:
About Bristol Business School, CHAIN Biotechnology: CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases.
Julian Shapley
Chief Scientific Officer and Founder of CellNovo
Dr. Shapley has a cross-functional engineering and scientific background, specialising in Microsystems for drug discovery. Dr Shapley worked with the International Space School at NASA in Houston, Texas. He is also the inventor of Cellnovo’s unique pump technology which serves as the cornerstone of the Cellnovo Mobile Diabetes Management System.
Follow Julian Shapley:
About CellNovo: CellNovo is a medical device company developing a wireless therapeutic system for diabetic patients.
Ema Kufel
Co-Founder, CEO of Prosoma
Co-Founder/CEO, Ema is an (MSc) Marketing Communications graduate and an expert in healthcare communications. Ema has vast experience in managing projects developing digital strategies within the National Health Service and the Department of Health in the UK. She is passionate about healthcare and innovation, key components of Prosoma.
Follow Ema Kufel:
About Prosoma: At Prosoma, we design world-leading digital therapeutics solutions for Oncology.
Marek Ostrowski
Founder of Prosoma
Founder, Marek finished Philosophy at the University of Wrocław, and then a post-graduate accredited Psychotherapy course, and Simonton’s Therapy Course. He specialises in working with oncological patients. From 2008, the founder and shareholder of a tech company, in which he was responsible for the development, innovation and management of strategic projects.
Follow Marek Ostrowski:
About Prosoma: At Prosoma, we design world-leading digital therapeutics solutions for Oncology.
Kate Hersov
Founder & Chief Medical Officer of Jumo Health
Follow Kate Hersov:
About Jumo Health: Jumo Health provides educational content and tools to help children and families understand, manage, and own their health.
Benjamin Swerner
Co-Founder of Relation Therapeutics
Casey Benjamin Swerner is the co-founder and COO of Relation Therapeutics.
Follow Benjamin Swerner:
About Relation Therapeutics: Relation Therapeutics engages in humanizing drug discovery and development.
Barry Shrier
Co-Founder & CEO of The Health-Tech Innovation LABS
Barry Shrier is Founder and CEO of Health-tech Innovation LABS, Barry is a serial entrepreneur with a history of successful exits .
Follow Barry Shrier:
About GIANT Health Events, The Health-Tech Innovation LABS: The Health-Tech Innovation LABS (HTI-LABS) are a group of businesses that improve the healthcare sector.
Farid Khan
Co-Founder of The Health-Tech Innovation LABS
Farid Khan obtained his Ph.D. from the University of Cambridge, UK where he studied the folding of GFP using fluorescence and NMR. Previously, he worked for a number of years at GlaxoSmithkline pharmaceuticals in fluorescence assay development for drug discovery projects.
Follow Farid Khan:
About Elucid mHealth, Pharmakure Ltd., Protein Technologies, The Health-Tech Innovation LABS: The Health-Tech Innovation LABS (HTI-LABS) are a group of businesses that improve the healthcare sector.
Ajan Reginald
Executive Director & Co-Founder of Cell Therapy
Follow Ajan Reginald:
About Celixir, Cell Therapy: Cell Therapy Ltd is a British pioneer in Regenerative Medicine.
Robert Dawson
Co-Founder of Vet-AI
Robert Dawson is the Co-Founder at Vet-AI.
Follow Robert Dawson:
About Vet-AI: Vet-AI is developing ground-breaking technologies that aim to prevent and predict conditions developing in animals.
Paul Hallett
Co-Founder of Vet-AI
Paul Hallett is the Co-Founder at Vet-AI
Follow Paul Hallett:
About Vet-AI: Vet-AI is developing ground-breaking technologies that aim to prevent and predict conditions developing in animals.
Ronan Cunningham
Founder and Chief Executive Officer of BrainWaveBank
Ronan has more than 20 years of experience in advanced engineering and product development. He was one of the founding members of ATA Engineering, an award-winning San Diego-based engineering company specializing in development of innovative hardware and software technologies for the aerospace and defence industries. His roles have included Director of Business Development and Director of New Technology Development. He is an Entrepreneur-in-Residence with the Northern Ireland Science Park. His expertise is in early stage technology development, innovation strategy, and technology commercialisation. He holds an MS in Aeronautics and Astronautics from MIT.
Follow Ronan Cunningham:
About BrainWaveBank, Cumulus Neuroscience: BrainWaveBank makes it possible to measure and track brain activity and cognitive performance for anyone, anytime, anywhere.
Alexandra Hussenot
Founder & CEO of Immersionn
Alexandra is the founder of Immersionn, the world’s first VR Discovery Engine and she is also the UK lead for ‘Women in Immersive Technologies’, a community of 1000 members that aims to empower European women working in XR. She is also 1 in 10 members of the UK5G Creative Industries working group reporting the department in charge of Digital, Medias, Culture and Sport (DCMS). Prior to this, Alexandra pursued an international business career at insurance firm, Allianz, managing an £80M global business. She has also worked all over Europe during her 11 years at Sony Ericsson (now Sony Mobile) and has solid experience designing and launching software and service products, particularly covering user experience design and continuous improvements. She also lead large scale operations for mobile phone repairs and remanufacturing.
Follow Alexandra Hussenot:
About Immersionn: Immersionn is a content discovery company. We allow people to discover VR content they would never find
Constantin Coussios
Founder & Chief Scientific Officer of OxSonics Therapeutics
Professor Constantin holds BA, MEng, MA and PhD degrees in Engineering from the University of Cambridge, and was elected to the first statutory chair in Biomedical Engineering at the University of Oxford in 2011, where he serves as the Director of the Institute of Biomedical Engineering. He is the author of over 100 peer-reviewed publications and 16 patents in the fields of drug delivery, acoustic cavitation and therapeutic ultrasound. Prof. Coussios received the UK’s Institute of Acoustics’ Young Person’s Award for Innovation in Acoustical Engineering in 2007, was elected as Secretary-General of the International Society for Therapeutic Ultrasound between 2006-2010 and was honoured with the Society’s Fred Lizzi award in 2012. He was elected as the youngest ever Fellow of the Acoustical Society of America in 2009 for contributions to biomedical ultrasound, and received the Society’s Bruce Lindsay award in 2012. Prof. Coussios leads the company’s technical development programmes.
Follow Constantin Coussios:
About OrganOx, OrthoSon, OxSonics Therapeutics, University of Oxford: OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Colin Story
Co-Founder & CEO of OxSonics Therapeutics
Colin Story brings over 20 years of medical technology and life sciences industrial experience, the majority held in commercial roles. After graduating with a BSc degree in Biological Sciences and a PhD in Molecular Biology he started his career at Amersham plc (now GE Healthcare) in 1997. Initially he held Product Development and Project Management roles in R&D and then latterly held a commercial role where he managed a £20m product portfolio. In 2005 he joined Isis Innovation Ltd, where he initiated, led and concluded a range of multi-£m transactions. In 2008 he went on to recruit and direct a Business Development team that managed over 200 medical science innovations emanating from Oxford University. In 2011 he joined OrganOx Ltd as Operations Director where he handled all operational and contractual aspects of the business that saw the company take a class III medical device from prototype into, and successfully through, first in man clinical trials. In January 2014 he became Co-Founder, Executive Director and the Chief Executive Officer of OxSonics® Ltd.
Follow Colin Story:
About OrthoSon, OxSonics Therapeutics: OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Ricky Towler
Founder of Middletons
Follow Ricky Towler:
About Middletons, Oak Tree Mobility: Middletons, accessible furniture and mobility specialists
Mikael Landau
Co-Founder of Heydoc
Mikael Landau is Co-Founder at Heydoc Limited.
Follow Mikael Landau:
About Heydoc: The integrated clinical system for managing your patients’ medical data and admin tasks.
James Roberts
CEO/Founder of mOm Incubators
Follow James Roberts:
About mOm Incubators, Royal Academy of Engineering, The Royal Society for the encouragement of Arts, Manufactures and Commerce (RSA): mOm is an inexpensive, electronically controlled, inflatable incubator constructed to decrease the number of premature child deaths.
Harry Destecroix
Founder and CEO of Ziylo
Follow Harry Destecroix:
About Ziylo: Ziylo has developed Biomimetic Glucose Binding Molecules (GBM) for Continuous Glucose Monitors (CGM) & Glucose Responsive Insulins (GRI)
Charlie Groome
Founder of Everna
Follow Charlie Groome:
About Everna: Everna is a biotech company developing novel therapeutics.
Benjamin T Dake
President & Founder of Aerovate Therapeutics
Ben Dake has 15 years experience as an Entrepreneur, Scientist and Biotech Investor. He founded Aerovate to develop therapies with the potential to meaningfully change the treatment of rare diseases. Informed by his training in diseases of aberrant proliferation he views PAH drug development through a unique lens focusing Aerovate on anti-proliferative therapies that directly address the root cause of disease.
Follow Benjamin T Dake:
About Aerovate Therapeutics: Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.